dsdsa

product

Good Quality Bimatoprost - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

We take "customer-friendly, quality-oriented, integrative, innovative" as objectives. "Truth and honesty" is our management ideal for Docetaxel Powder, Degarelix, China Melatonine Powder, As an expert specialized in this field, we are committed to solving any problem of high temperature protection for users.
Good Quality Bimatoprost - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai Detail:

Product name Tofacitinib Citrate
Synonyms (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate; CP 690500-10; CP 690550-10; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate
CAS No. 540737-29-9
Appearance Off white to white powder
Molecular Formula C16H20N6O.C6H8O7
Molecular Weight 504.50
Application Pharmaceutical grade or research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Tofacitinib Citrate (CAS #540737-29-9)

ITEMS

STANDARDS

RESULTS

Appearance

Off white to white powder

Off white powder

Identification

HPLC; IR; HNMR

Complies

Solubility

Soluble in DMSO at 100mg/ml, very poorly soluble in ethanol, sparingly soluble in water etc.

Complies

Loss on Drying

≤0.5%

0.12%

Residue on ignition

≤0.1%

0.05%

Heavy metals

≤10ppm

Complies

Related Substances

Diastereomer (RS+SR) ≤0.1%

Single Impurity ≤0.15%

Total impurities ≤1.0%

0.05%

0.14%

0.18%

Enantiomorphism Isomers

≤0.2%

Complies

Residual Solvents

Ethanol ≤5000ppm

Methanol ≤3000ppm

Toluene ≤890ppm

Complies

Citrate Content

36.2%~40%

37.8%

Purity

≥99.0%

99.38%

Assay

60.68%~63.16% of Tofacitinib INN

98%~102% of Tofacitinib Citrate INN

62.04%

 

99.12%

Conclusion:Complies

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Good Quality Bimatoprost - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Good Quality Bimatoprost - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Good Quality Bimatoprost - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures


Related Product Guide:

Adhering into the principle of "quality, provider, performance and growth", we now have gained trusts and praises from domestic and intercontinental consumer for Good Quality Bimatoprost - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai , The product will supply to all over the world, such as: America, Roman, Korea, If you are for any reason unsure which product to select, do not hesitate to contact us and we will be delighted to advise and assist you. This way we will be providing you with all the knowledge needed to make the best choice. Our company strictly follows "Survive by good quality, Develop by keeping good credit. " operation policy. Welcome all the clients old and new to visit our company and talk about the business. We are looking for more and more customers to create the glorious future.
  • Adhering to the business principle of mutual benefits, we have a happy and successful transaction, we think we will be the best business partner.
    5 Stars By Ivan from Austria - 2017.09.30 16:36
    This is a reputable company, they have a high level of business management, good quality product and service, every cooperation is assured and delighted!
    5 Stars By Arthur from Morocco - 2017.02.18 15:54
    Write your message here and send it to us